<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only in the combination daclatasvir/sofosbuvir:

Possibly abrupt onset of bradycardia, that can have fatal consequences</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the daclatasvir/sofosbuvir combination</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>With the exception of the dexamethasone administered in a single dose. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>-with rifampicin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of daclatasvir by the inhibitor.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of daclatasvir must be decreased to 30 mg 1 time per day in case of administration with the inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns Wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
